Invivoscribe

Invivoscribe is a leading provider of clinically-validated personalized molecular diagnostics in leukemias, lymphomas and other lymphoproliferative diseases. Invivoscribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation Research Use Only testing reagents and controls. Invivoscribe also provides CE-marked in vitro diagnostic products. We provide access to cutting edge testing to physicians and cancer centers world wide, enabling doctors to determine the most successful method of treatment for each patient. The company and its subsidiaries provide one stop comprehensive care for patients in over 50 countries. Invivoscribe's CE-marked IVD products are used to identify, classify and monitor leukemias, lymphomas and other lymphoproliferative diseases. The company's CLIA- and CAP-accredited clinical reference laboratories, LabPMM LLC & LabPMM GmbH, are the only clinical laboratories outside Japan licensed to perform FLT3 biomarker testing, and the only laboratories in the world licensed to determine the mutation status of both FLT3 and NPM1.

Major Product Lines:

• IVD-products to identify, classify and monitor leukemias, lymphomas and other lymphoproliferative disease.
• B-Cell and T-Cell rearrangement clonality assays
• CE- marked Gene Clonality, gene Translocation Gene Mutation Assays.
• DNA/RNA/Lyophilized Cell Controls, Sensitivity Panels and Proficiency Panels.

For more information, please visit: www.invivoscribe.com